[go: up one dir, main page]

NO20063629L - Myokardial perfusjonsbildebehandling ved anvendelse av adenosinagonister - Google Patents

Myokardial perfusjonsbildebehandling ved anvendelse av adenosinagonister

Info

Publication number
NO20063629L
NO20063629L NO20063629A NO20063629A NO20063629L NO 20063629 L NO20063629 L NO 20063629L NO 20063629 A NO20063629 A NO 20063629A NO 20063629 A NO20063629 A NO 20063629A NO 20063629 L NO20063629 L NO 20063629L
Authority
NO
Norway
Prior art keywords
myocardial perfusion
perfusion imaging
adenosine agonists
adenosine
agonists
Prior art date
Application number
NO20063629A
Other languages
English (en)
Other versions
NO337132B1 (no
Inventor
Luiz Belardinelli
Mitchell Rosner
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20063629L publication Critical patent/NO20063629L/no
Publication of NO337132B1 publication Critical patent/NO337132B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

En hjertesynliggjøringsfremgangsmåte som blir utført ved å administrere én eller flere adenosin-A2A-adenosinreseptoragonister til et menneske som gjennomgår hjertesynliggjøring i tillegg til farmasøytiske preparater som omfatter minst én A2A-reseptoragonist, minst én flytende bærer og minst ett tilleggsløsningsmiddel.
NO20063629A 2004-01-27 2006-08-10 Farmasøytisk preparat som omfatter en A2A-reseptoragonist og dets anvendelse i en fremgangsmåte for å frembringe koronar vasodilasjon, samt i en fremgangsmåte for myokard perfusjonsavbildning. NO337132B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/002304 WO2005082379A1 (en) 2004-01-27 2004-01-27 Myocardial perfusion imaging using adenosine receptor agonists

Publications (2)

Publication Number Publication Date
NO20063629L true NO20063629L (no) 2006-10-26
NO337132B1 NO337132B1 (no) 2016-01-25

Family

ID=34912870

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063629A NO337132B1 (no) 2004-01-27 2006-08-10 Farmasøytisk preparat som omfatter en A2A-reseptoragonist og dets anvendelse i en fremgangsmåte for å frembringe koronar vasodilasjon, samt i en fremgangsmåte for myokard perfusjonsavbildning.

Country Status (15)

Country Link
EP (2) EP2366396B1 (no)
JP (1) JP4818127B2 (no)
KR (1) KR101143826B1 (no)
CN (1) CN1905887A (no)
AU (1) AU2004316372B2 (no)
CA (2) CA2554169C (no)
CY (2) CY1114928T1 (no)
DK (2) DK2366396T3 (no)
ES (2) ES2426913T3 (no)
IL (1) IL177119A (no)
NO (1) NO337132B1 (no)
NZ (1) NZ548794A (no)
PT (2) PT2366396E (no)
SI (2) SI1708721T1 (no)
WO (1) WO2005082379A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
WO2001062979A2 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Dentification of partial agonists of the a2a adenosine receptor
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
JP2005538190A (ja) 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング
RU2007114908A (ru) 2004-10-20 2008-10-27 Си Ви ТЕРАПЬЮСи Ви ТЕРАПЬЮТИКСИКС Применение агонистов аденозиновых рецепторов a2a
CA2640089C (en) 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
CA2716501A1 (en) * 2008-02-29 2009-09-03 King Pharmaceuticals Research And Development, Inc. Crystal forms of 2-{2-[(cyclohexyl)methylene]hydrazino}adenosine
RU2011115815A (ru) * 2008-09-29 2012-11-10 Гайлид Сайэнсиз, Инк. (Us) Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии
JP2011098990A (ja) * 2011-02-21 2011-05-19 Gilead Palo Alto Inc アデノシン受容体作動薬を使用する心筋灌流イメージング方法
RU2502461C1 (ru) * 2012-06-04 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "РКНПК" Минздравсоцразвития России) Способ диагностики ишемии миокарда у больных кардиальным синдромом х
US20190240247A1 (en) * 2016-09-01 2019-08-08 Leiutis Pharmaceuticals Pvt. Ltd. Pharmaceutical formulations of regadenoson

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6026317A (en) * 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
WO2001062979A2 (en) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Dentification of partial agonists of the a2a adenosine receptor
JP2005538190A (ja) * 2002-07-29 2005-12-15 シーブイ・セラピューティクス・インコーポレイテッド 心筋潅流イメージング

Also Published As

Publication number Publication date
SI1708721T1 (sl) 2013-10-30
SI2366396T1 (sl) 2013-10-30
EP1708721B1 (en) 2013-08-07
PT1708721E (pt) 2013-10-02
PT2366396E (pt) 2013-10-03
KR101143826B1 (ko) 2012-05-11
ES2426913T8 (es) 2013-12-16
EP1708721A1 (en) 2006-10-11
NO337132B1 (no) 2016-01-25
ES2428843T3 (es) 2013-11-11
IL177119A (en) 2011-07-31
ES2428843T8 (es) 2013-12-26
DK2366396T3 (da) 2013-09-08
CY1114928T1 (el) 2016-12-14
EP2366396A1 (en) 2011-09-21
CA2691611A1 (en) 2005-09-09
JP2007519718A (ja) 2007-07-19
AU2004316372B2 (en) 2011-05-12
EP2366396B1 (en) 2013-08-07
JP4818127B2 (ja) 2011-11-16
WO2005082379A8 (en) 2006-01-19
NZ548794A (en) 2009-07-31
DK1708721T3 (da) 2013-09-08
HK1162139A1 (en) 2012-08-24
WO2005082379A1 (en) 2005-09-09
ES2426913T3 (es) 2013-10-25
CY1115926T1 (el) 2017-01-25
CN1905887A (zh) 2007-01-31
KR20060130630A (ko) 2006-12-19
CA2554169C (en) 2010-03-16
IL177119A0 (en) 2008-03-20
CA2554169A1 (en) 2005-09-09
AU2004316372A1 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
NO20051059L (no) Myokardiell perfusjonsavbildning ved a benytte A2A-reseptoragonister
NO20063629L (no) Myokardial perfusjonsbildebehandling ved anvendelse av adenosinagonister
Müller et al. Recent developments in adenosine receptor ligands and their potential as novel drugs
Landoni et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials
NO20072540L (no) Anvendelse av A2A-adenosinreseptoragonist
Rogstad et al. Chemical decomposition of 5-aza-2′-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry
NO20091734L (no) Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse
DOP2006000008A (es) Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
Reid et al. In vivo adenosine receptor preconditioning reduces myocardial infarct size via subcellular ERK signaling
EP3106169A1 (en) Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
Zeng et al. Stress hyperglycemia ratio and long‐term prognosis in patients with acute coronary syndrome: a multicenter, nationwide study
BR112015002249A2 (pt) composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo
Tupling et al. Silver ions induce Ca2+ release from the SR in vitro by acting on the Ca2+ release channel and the Ca2+ pump
Kehraus et al. Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique adenosine derivative
Palani et al. Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications
Pfeffer et al. Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation
Rodríguez-Nóvoa et al. Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin
Kudej et al. Nitric oxide, an important regulator of perfusion-contraction matching in conscious pigs
EP1853280A4 (en) COMPOSITIONS AND METHODS OF TREATING AND PREVENTING CARDIOMYOPATHY AND HERBAL DISEASE
Larsson et al. Female advantage in AMI mortality is reversed in patients with type 2 diabetes in the Skaraborg Project
WO2006127842A3 (en) Tracers for monitoring the activity of sodium/glucose cotransporters in health and disease
HUP0400758A2 (hu) Kardiális perfúzió és kardiális inflammáció egyidejű duális izotópos leképezése
Park et al. Therapeutic effect of fimasartan in a rat model of myocardial infarction evaluated by cardiac positron emission tomography with [18F] FPTP
WO2007137135A3 (en) Rotenone analogs: method of preparation and use
NO20090495L (no) Fremgangsmater, sammensetninger, enhetsdoseringsformer og kit for stresstesting med reduserte bivirkninger

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GILEAD SCIENCES, US

MK1K Patent expired